News
Introduction It’s time to discuss Steel Dynamics (NASDAQ:STLD). This Indiana-based steel giant is one of America’s best-performing industrial stocks and one of the few...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow I’m Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a...
News
This article was written by Follow Hey there! My focus here is to provide you with insightful rating analysis on the world’s leading financial...
News
This article was written by Follow As a self-taught retail investor, I’m interested to share insights through thoughtful, research-driven articles. I’m glad you’ve taken...
News
On our last coverage of Alibaba (NYSE:BABA), we acknowledged that the bulls were better setup, but did not attach a buy rating on that...
News
2023 will be a big year for AbbVie. The company’s transition from a Humira-dependent enterprise to one with multiple green shoots is here. Is...
News
Listen to the podcast below or on the go via Apple Podcasts or Spotify. Green Growth Giants’ Owen Clendenin shares where most lithium comes...
News
Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify This is an abridged conversation from Seeking Alpha’s Investing Experts...
News
Co-authored with “Hidden Opportunities.” The U.S. economy continues to slow down as the Federal Reserve continues its inflation containment efforts. While rates have been...
News
Author’s Note: This article was published on iREIT on Alpha in April of 2022. Dear subscribers, So, AvalonBay (NYSE:AVB). I’ve been a proponent of...
News
As fears about Beijing’s potential invasion of Taiwan once again gain traction and prompt investors like Warren Buffett to unwind their long positions in...
News
It happens to everyone. It will happen to you, too. There’s no escaping it. Sooner or later, you’ll be toiling away at your nine-to-five,...
News
Kinnate Biopharma (NASDAQ:KNTE) develops small molecule kinase inhibitors to treat genomically defined cancers. The company has two molecules in the clinic, exarafenib and KIN-3248....
